TBL1X Antibody

What is TBL1X and why is it important in molecular research?

TBL1X is a WD40 repeat-containing protein that functions as an essential subunit of the NCoR-SMRT complex, which is the major thyroid hormone receptor (TR) corepressor involved in T3-regulated gene expression. The importance of TBL1X in research stems from its critical role in:

• Transcriptional regulation via the corepressor complex

• Thyroid hormone signaling pathways

• Gene expression control mechanisms

• Association with central hypothyroidism and hearing loss when mutated

Recent studies have established that TBL1X defects are associated with central hypothyroidism, highlighting its significance in endocrine research . Additionally, as part of the corepressor complex, TBL1X is involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units, making it relevant for studies on gene expression regulation .

What applications are TBL1X antibodies most commonly used for?

TBL1X antibodies are utilized across multiple experimental applications, with varying recommended dilutions depending on the specific application and antibody. The most common applications include:

It's crucial to optimize antibody dilutions for each specific experimental system to obtain optimal results, as sensitivity can be sample-dependent .

How should researchers choose between polyclonal and monoclonal TBL1X antibodies?

The choice between polyclonal and monoclonal TBL1X antibodies depends on your specific research objectives:

Polyclonal antibodies (e.g., 13540-1-AP):

• Recognize multiple epitopes on the TBL1X protein

• Often provide higher sensitivity for detecting low-abundance proteins

• Useful for applications requiring robust signal detection

• Better for detecting denatured proteins in Western blots

• May have higher batch-to-batch variability

Monoclonal antibodies (e.g., 66955-1-Ig):

• Recognize a single epitope with high specificity

• Provide consistent results with minimal batch-to-batch variation

• Ideal for distinguishing between closely related proteins

• Often preferred for quantitative applications

• Better for applications requiring high reproducibility

For critical experiments, validation with both antibody types may be advisable. If detecting TBL1X in complex samples where cross-reactivity might be an issue, monoclonal antibodies often provide better specificity .

What reactivity should researchers expect from commercially available TBL1X antibodies?

Most commercial TBL1X antibodies have been tested and validated for cross-reactivity with multiple species. Based on the search results, the typical reactivity profiles include:

When studying non-human models, it's advisable to first confirm antibody cross-reactivity through pilot experiments, especially for species not listed in the manufacturer's validation data .

How can researchers experimentally distinguish between TBL1X and its closely related homologs (TBL1XR1 and TBL1Y)?

Distinguishing between TBL1X and its homologs presents a significant challenge due to their structural similarities. A methodological approach includes:

• Epitope-specific antibodies: Select antibodies recognizing unique regions:

  • TBL1X-specific antibodies target unique sequences not present in TBL1XR1/TBL1Y

  • For example, antibodies targeting AA 100-200 region of TBL1X (ABIN7270901) can provide specificity

• Molecular weight differentiation:

  • TBL1X: Observed at 57 kDa

  • TBL1XR1: Slightly different molecular weight

  • Use high-resolution SDS-PAGE with proper controls

• Combined knockdown/knockout validation:

  • Perform siRNA knockdown or CRISPR knockout of TBL1X

  • Verify specificity by demonstrating loss of signal with TBL1X-specific antibodies but not with antibodies targeting the homologs

  • TBL1X CRISPR/Cas9 KO plasmids are commercially available for this purpose

• Tissue-specific expression patterns:

  • TBL1Y shows differential expression compared to TBL1X across tissues

  • TBL1Y is not expressed in leukocytes, while TBL1X is more broadly expressed

• Functional validation:

  • GAL4DBD-fused TBL1Y does not repress promoter activity, unlike other TBL1 family members

  • This functional difference can be exploited in reporter assays to distinguish them

When absolute specificity is required, consider using multiple approaches in combination rather than relying on a single method .

What considerations are important when investigating TBL1X's role in thyroid hormone signaling pathways?

TBL1X plays a complex role in thyroid hormone (TH) signaling that requires careful experimental consideration:

• Gene context-dependent effects:

  • TBL1X can act as both corepressor and coactivator depending on gene context

  • Knockdown and mutation studies show differential effects on various T3-regulated genes

  • For example, TBL1X downregulation increases expression of KLF9, CPT1A, and PCK1 but decreases DIO1 expression upon T3 stimulation

• Tissue-specific considerations:

  • Expression effects vary between different tissues (liver, pituitary, WAT, kidney)

  • Design tissue-specific experiments with appropriate controls

  • Consider the dominant TR isoform (TRα vs. TRβ) in the tissue being studied

• Experimental design for TH signaling studies:

  • Include T3 dose-response experiments (e.g., 0-10 nM T3)

  • Monitor both positively and negatively T3-regulated genes

  • Suggested T3-regulated genes to monitor: DIO1, KLF9, THRSP, CPT1A, G6PC1, PCK1, FBP1, HMGCS2

• Mutation-specific effects:

  • Different TBL1X mutations may have distinct effects on TH action

  • The TBL1X N365Y mutation affects the expression of CPT1A, G6PC1, PCK1, FBP1, and ELOVL2, but not KLF9 and HMGCS2

What are the optimal protocols for using TBL1X antibodies in chromatin immunoprecipitation (ChIP) experiments?

Chromatin immunoprecipitation with TBL1X antibodies requires careful optimization. A detailed protocol includes:

• Crosslinking and chromatin preparation:

  • Fix cells with 1% formaldehyde for 10 minutes at room temperature

  • Quench with 125 mM glycine for 5 minutes

  • Lyse cells and sonicate chromatin to 200-500 bp fragments

  • Verify fragment size by agarose gel electrophoresis

• Antibody selection and validation:

  • Use ChIP-validated TBL1X antibodies (e.g., 13540-1-AP)

  • Perform preliminary validation using known TBL1X binding sites

  • Include appropriate negative controls (IgG) and positive controls (e.g., histones)

• Immunoprecipitation optimization:

  • Pre-clear chromatin with protein A/G beads

  • Use 2-5 μg of TBL1X antibody per IP reaction

  • Incubate overnight at 4°C with rotation

  • Include appropriate washing steps to reduce background

• Special considerations for TBL1X ChIP:

  • TBL1X functions as part of larger protein complexes (NCoR/SMRT)

  • Consider dual ChIP with other complex components (e.g., HDAC3)

  • TBL1X interacts with histones H2B, H3a, and H4

  • Design primers targeting known nuclear receptor binding sites

• Data analysis and interpretation:

  • Normalize to input chromatin

  • Compare enrichment at target sites versus negative control regions

  • Consider ChIP-seq for genome-wide binding analysis

  • Use bioinformatics to identify co-enrichment with other nuclear receptor complex components

This protocol should be optimized for each cell type and experimental condition to ensure reliable and reproducible results .

How should researchers interpret contradictory results when studying TBL1X function in different cellular contexts?

Interpreting contradictory results regarding TBL1X function requires systematic analysis and consideration of multiple factors:

• Cell type and tissue-specific effects:

  • TBL1X function varies between different cell types and tissues

  • In HepG2 cells, TBL1X acts as a corepressor for some genes (KLF9, CPT1A, PCK1) but a coactivator for others (DIO1)

  • In iHeps with TBL1X N365Y mutation, different patterns are observed

  • Methodically document these differences rather than attempting to force consistency

• Experimental approach differences:

  • Knockdown vs. mutation approaches can yield different results

  • Transient vs. stable modifications affect outcome

  • Complete the following comparative analysis table:

  Approach	Advantages	Limitations	Example Finding
  siRNA knockdown	Rapid, high efficiency	Transient, potential off-targets	Increased KLF9, CPT1A, PCK1 expression
  CRISPR knockout	Complete protein loss, stable	Potential compensation	Variable depending on cell type
  Point mutation	Physiologically relevant	Mutation-specific effects	TBL1X N365Y: decreased expression of CPT1A, G6PC1, PCK1

• Protein complex context:

  • TBL1X functions as part of larger protein complexes

  • The N-CoR complex includes N-CoR1, N-CoR2, HDAC3, TBL1R, CORO2A, and GPS2

  • Variation in expression of other complex components can alter TBL1X function

  • Consider analyzing all complex components simultaneously

• Hormone concentration and treatment duration:

  • T3 concentration affects TBL1X-mediated gene regulation

  • Document exact hormone concentrations and exposure times

  • Consider performing full dose-response and time-course experiments

When facing contradictory results, systematically document all experimental differences and consider that TBL1X may genuinely perform different functions depending on context, rather than assuming one result is "correct" .

What are the best practices for validating TBL1X antibody specificity in experimental applications?

Thorough validation of TBL1X antibody specificity is critical for reliable research findings. A comprehensive validation approach includes:

• Genetic validation methods:

  • siRNA knockdown: Verify reduced signal after TBL1X siRNA treatment

  • CRISPR knockout: Confirm complete loss of signal in TBL1X knockout cells

  • Overexpression: Demonstrate increased signal in cells overexpressing TBL1X

  • Implement at least two of these approaches for robust validation

• Cross-reactivity assessment:

  • Test on samples from TBL1X knockout/knockdown models

  • Evaluate potential cross-reactivity with homologs (TBL1XR1, TBL1Y)

  • Test antibody in cells lacking target protein expression

  • Pre-absorb antibody with immunizing peptide to demonstrate specificity

• Application-specific validations:

  Application	Validation Approach	Expected Result	Citation
  Western Blot	Detect band at correct MW (57 kDa)	Single band at expected size
  IHC	Staining in positive control tissues (brain, breast cancer)	Specific signal in expected regions
  IF/ICC	Subcellular localization consistent with known TBL1X distribution	Nuclear localization
  IP	Mass spectrometry confirmation of pulled-down proteins	TBL1X and known interactors identified

• Multi-antibody concordance:

  • Compare results from multiple antibodies targeting different TBL1X epitopes

  • For example, compare antibody targeting AA 100-200 (ABIN7270901) with one targeting different regions

  • Consistent results across antibodies increase confidence in specificity

• Batch-to-batch validation:

  • Implement routine quality control testing for each new antibody lot

  • Maintain reference samples to compare antibody performance over time

  • Document lot numbers in publications to facilitate reproducibility

How can TBL1X antibodies be used to investigate the role of TBL1X in diseases beyond thyroid disorders?

TBL1X has emerging roles in multiple diseases that can be investigated using appropriately validated antibodies:

• Cancer research applications:

  • TBL1X is overexpressed in diffuse large B-cell lymphoma (DLBCL)

  • High TBL1X expression correlates with poor clinical outcomes in DLBCL regardless of molecular subtype

  • Methodological approach:

    • Use TBL1X antibodies for tissue microarray analysis to correlate expression with patient outcomes

    • Combine with markers of cell proliferation and apoptosis

    • Conduct ChIP-seq to identify cancer-specific TBL1X binding sites

• Deafness and hearing loss research:

  • TBL1X deletions have been associated with hearing loss

  • TBL1X antibodies can be used to study expression in:

    • Inner ear tissues

    • Auditory neuronal pathways

    • Developmental time courses of ear formation

• Developmental disorders:

  • TBL1X is located adjacent to the ocular albinism gene

  • It may be involved in the pathogenesis of ocular albinism with late-onset sensorineural deafness

  • Use antibodies to study developmental expression patterns

• Metabolic disease investigation:

  • TBL1X affects expression of metabolic genes in liver cells

  • Research strategies:

    • Immunostaining of liver biopsies from patients with metabolic disorders

    • CoIP experiments to identify altered protein interactions in disease states

    • ChIP-seq to map TBL1X binding to metabolic gene promoters

Researchers should optimize antibody conditions for each tissue type and application, as signal strength and background may vary considerably between different disease tissues .

What are the most effective methods for studying interactions between TBL1X and other components of the corepressor complex?

Investigating TBL1X interactions within the corepressor complex requires specialized approaches:

• Co-Immunoprecipitation (CoIP) strategies:

  • Use TBL1X antibodies to pull down native protein complexes

  • Reverse CoIP: Use antibodies against known interactors (NCoR, SMRT, HDAC3)

  • Sequential CoIP to identify specific subcomplexes

  • Western blot detection of co-precipitated proteins

  • Protocol recommendations:

    • Use gentle lysis buffers to preserve protein-protein interactions

    • Include protease and phosphatase inhibitors

    • Consider crosslinking for transient interactions

• Proximity ligation assay (PLA):

  • Visualize protein-protein interactions in situ

  • Combine TBL1X antibodies with antibodies against interacting partners

  • Quantify interaction signals at subcellular resolution

  • Particularly useful for detecting changes in interactions under different conditions

• ChIP-reChIP (sequential ChIP):

  • First ChIP with TBL1X antibody

  • Second ChIP with antibody against another complex component

  • Identifies genomic sites where both proteins co-occupy

  • Helps distinguish different functional subcomplexes

• Biochemical complex isolation:

  • Size exclusion chromatography to separate intact complexes

  • Use TBL1X antibodies for Western blot analysis of fractions

  • Identify which fractions contain TBL1X and other components

  • Mass spectrometry to identify all components in TBL1X-containing fractions

• Functional interaction studies:

  • Use reporter gene assays with TBL1X antibodies for ChIP

  • Compare wild-type vs. mutant TBL1X (e.g., N365Y)

  • Assess how mutations affect complex assembly and function

  • Document interaction changes upon ligand stimulation (e.g., T3)

These methodologies can be combined to build a comprehensive understanding of TBL1X's dynamic interactions within the corepressor complex under different physiological and pathological conditions .

What technical challenges might researchers encounter when using TBL1X antibodies in complex tissue samples?

Working with TBL1X antibodies in complex tissues presents several technical challenges that require specific optimization strategies:

• Background and non-specific binding:

  • Challenge: High background in tissues with abundant nuclear proteins

  • Solution:

    • Extensive blocking (3-5% BSA or 5-10% normal serum)

    • Include additional washing steps with increased stringency

    • Use monoclonal antibodies for higher specificity in complex samples

    • For IHC, consider biotin-free detection systems to reduce endogenous biotin binding

• Epitope masking in fixed tissues:

  • Challenge: Formalin fixation can mask TBL1X epitopes

  • Solution:

    • Optimize antigen retrieval conditions

    • For brain tissue: use TE buffer pH 9.0 as recommended

    • For other tissues: citrate buffer pH 6.0 as alternative

    • Test multiple antibodies targeting different epitopes

• Variable expression levels across tissues:

  • Challenge: TBL1X expression varies significantly between tissues

  • Solution:

    • Adjust antibody concentration for each tissue type

    • For brain: 1:50-1:500 dilution recommended for IHC

    • For breast cancer: 1:1000-1:4000 dilution recommended

    • Run pilot studies to determine optimal concentration for your tissue

• Discrimination from homologs:

  • Challenge: Cross-reactivity with TBL1XR1 and TBL1Y in male tissues

  • Solution:

    • Use antibodies specifically validated to distinguish between homologs

    • Include appropriate control samples (e.g., tissues known to express only TBL1X)

    • Consider parallel detection with homolog-specific antibodies

• Preservation of protein complexes:

  • Challenge: Standard fixation may disrupt TBL1X-containing complexes

  • Solution:

    • For CoIP applications, use gentler crosslinking approaches

    • For IF, consider dual staining with antibodies against known complex partners

    • Optimize fixation time to balance structural preservation and epitope accessibility

Researchers should document all optimization steps and include appropriate positive and negative controls in each experiment to ensure reliable and reproducible results .

How can researchers effectively utilize TBL1X antibodies to investigate the differential effects of TBL1X on thyroid hormone regulated genes?

To investigate TBL1X's complex effects on thyroid hormone-regulated genes, researchers should employ a multi-faceted approach using TBL1X antibodies:

• ChIP-seq experimental design:

  • Use validated TBL1X antibodies for chromatin immunoprecipitation

  • Compare TBL1X binding patterns with/without T3 treatment

  • Include parallel ChIPs for TR and other corepressor components

  • Analyze binding patterns at both positively and negatively regulated T3 target genes

  • Focus on genes showing differential regulation:

    • Positively regulated genes affected by TBL1X: KLF9, CPT1A, PCK1

    • Negatively regulated by TBL1X: DIO1

• Gene-specific ChIP protocol:

  • Design primers for key target genes identified in previous studies:

    • For "corepressor" function: KLF9, CPT1A, PCK1 promoters

    • For "coactivator" function: DIO1 promoter regions

  • Include control regions not regulated by TBL1X

  • Analyze TBL1X occupancy at different time points after T3 treatment

• Integrative functional studies:

  • Combine TBL1X ChIP with TBL1X knockdown/mutation studies

  • Use TBL1X antibodies to verify knockdown efficiency

  • Compare TBL1X occupancy in wild-type vs. mutant cells (e.g., N365Y mutation)

  • Analyze changes in histone modifications at TBL1X binding sites

• Tissue-specific considerations:

  • Different tissues show varied TBL1X effects on gene expression:

    • White adipose tissue (WAT): Increased MCT8 expression in TBL1X mutants

    • Kidney: Altered T3-regulated gene expression

    • Pituitary: Lower TRα1 mRNA but increased Tshβ expression in mutants

  • Optimize antibody conditions for each tissue type

• Data interpretation framework:

  • Document gene-specific changes in TBL1X binding upon T3 treatment

  • Correlate changes in occupancy with gene expression changes

  • Consider the kinetics of TBL1X recruitment/dismissal at different target genes

  • Interpret results in the context of the "coactivator vs. corepressor" paradigm

This approach will help elucidate the molecular mechanisms underlying TBL1X's differential effects on thyroid hormone-regulated genes and provide insights into its dual role as both corepressor and coactivator .

What are the emerging applications of TBL1X antibodies in single-cell and spatial transcriptomics research?

TBL1X antibodies are increasingly being integrated with cutting-edge single-cell and spatial technologies:

• Single-cell protein analysis:

  • TBL1X antibodies can be conjugated with heavy metals for mass cytometry (CyTOF)

  • Enable simultaneous detection of TBL1X with other transcriptional regulators

  • Applications in heterogeneous samples such as:

    • Thyroid tissue to identify cell populations with differential TBL1X expression

    • Developing brain to map TBL1X expression during neurogenesis

    • Cancer samples to identify TBL1X-high subpopulations

• Spatial proteomics applications:

  • Multiplex immunofluorescence with TBL1X antibodies

  • Co-localization studies with other corepressor components

  • Tissue-specific expression mapping, particularly relevant for:

    • Pituitary gland where TBL1X affects TRα1 and Tshβ expression

    • Inner ear structures related to hearing loss phenotypes

    • Liver lobules where metabolic gene regulation occurs

• Integrated multi-omics approaches:

  • Combine TBL1X antibody-based techniques with transcriptomics:

    • Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq)

    • Simultaneous detection of TBL1X protein and gene expression profiles

    • Integration with chromatin accessibility data (ATAC-seq)

  • Allows correlation between TBL1X protein levels and target gene expression

• Methodological considerations:

  • Antibody validation is particularly critical for single-cell applications

  • Optimize fixation and permeabilization for nuclear protein detection

  • Consider fluorophore selection to minimize spectral overlap with other markers

  • Include appropriate isotype controls and titration series

These emerging applications will provide unprecedented insights into TBL1X's cell type-specific functions and its role in development, disease, and response to hormonal stimulation .

How are TBL1X antibodies contributing to understanding the molecular mechanisms of congenital hypothyroidism?

TBL1X antibodies play a pivotal role in elucidating the molecular mechanisms underlying TBL1X-associated congenital hypothyroidism:

• Mechanistic studies of TBL1X mutations:

  • Antibodies enable comparative analysis of wild-type vs. mutant TBL1X

  • Specific mutations associated with central hypothyroidism:

    • N365Y mutation affects binding to corepressor complex components

    • Several TBL1X mutations have been identified in patients with central hypothyroidism and hearing loss

  • Methodological approaches:

    • Compare protein expression, localization, and stability of WT vs. mutant TBL1X

    • Analyze changes in protein-protein interactions using coimmunoprecipitation

    • Assess DNA binding capability using ChIP assays

• Developmental expression mapping:

  • Track TBL1X expression during hypothalamic-pituitary axis development

  • Investigate expression patterns in:

    • Human hypothalami and pituitary glands

    • Animal models of thyroid development

  • Spatiotemporal mapping of TBL1X expression relative to thyroid hormone receptors

• Functional analysis of the corepressor complex:

  • Use TBL1X antibodies to isolate intact corepressor complexes

  • Compare complex composition in normal vs. hypothyroid states

  • Investigate how TBL1X mutations affect:

    • Complex assembly and stability

    • Recruitment to thyroid hormone receptor target genes

    • Response to T3 treatment

• Translational research applications:

  • Patient-derived cell models:

    • iPS cells from patients with TBL1X mutations

    • Differentiation into relevant cell types (e.g., thyroid cells)

    • Analysis of TBL1X expression, localization, and function

  • Potential therapeutic targeting:

    • Screening compounds that might restore proper complex formation

    • Monitoring treatment effects on TBL1X expression and function

These approaches are providing crucial insights into how TBL1X mutations lead to central hypothyroidism and may guide future development of personalized therapeutic strategies for affected patients .

What quality control measures should be implemented when working with TBL1X antibodies across different experimental batches?

Maintaining experimental consistency when working with TBL1X antibodies across multiple batches requires rigorous quality control:

• Batch validation protocol:

  • Test each new antibody lot against a reference standard

  • Maintain frozen aliquots of positive control samples

  • Perform side-by-side comparison between old and new lots using:

    • Western blot to confirm correct molecular weight (57 kDa)

    • IHC on standard positive control tissues (brain, breast cancer)

    • IF to verify expected subcellular localization

• Quantitative performance metrics:

  • Establish quantitative acceptance criteria:

    • Signal-to-noise ratio in Western blots

    • Staining intensity scores in IHC applications

    • Background levels in negative control samples

  • Document lot-specific optimal dilutions:

    • Western Blot: 1:500-1:2400 (polyclonal) or 1:5000-1:100000 (monoclonal)

    • IHC: 1:50-1:500 (polyclonal) or 1:1000-1:4000 (monoclonal)

• Reference controls for each application:

  Application	Positive Control	Negative Control	Expected Result	Citation
  WB	Mouse pancreas tissue	TBL1X knockdown cells	57 kDa band
  IHC	Mouse brain tissue	Primary antibody omission	Nuclear staining
  IF/ICC	HEK-293 cells	TBL1X knockdown cells	Nuclear localization

• Storage and handling standardization:

  • Store according to manufacturer recommendations:

    • -20°C with 50% glycerol

    • Avoid repeated freeze-thaw cycles

  • Implement standardized aliquoting procedures

  • Document storage conditions and time since thawing

• Comprehensive record-keeping:

  • Maintain a database of antibody performance metrics

  • Record lot numbers in all experimental documentation

  • Include batch information in publications to facilitate reproducibility

  • Note any batch-specific optimization requirements

Implementing these quality control measures will minimize batch-related variability and enhance the reliability and reproducibility of experiments using TBL1X antibodies .

What strategies can researchers employ to optimize TBL1X antibody performance in challenging samples with low target expression?

Detecting TBL1X in samples with low expression levels requires specialized optimization strategies:

• Signal amplification techniques:

  • Tyramide signal amplification (TSA) for IHC/IF:

    • Can increase sensitivity 10-100 fold

    • Particularly useful for detecting low TBL1X levels in tissues

    • Protocol adaptation: Use primary TBL1X antibody at 1:1000, followed by HRP-conjugated secondary and tyramide amplification

  • Polymer-based detection systems:

    • Multimer technology with multiple secondary antibodies

    • Increases signal without increasing background

• Sample preparation optimization:

  • Protein extraction enhancement:

    • Use specialized nuclear extraction buffers

    • Include protease inhibitors to prevent degradation

    • Consider subcellular fractionation to concentrate nuclear proteins

  • Antigen retrieval optimization:

    • Extended retrieval times for challenging samples

    • Test both TE buffer pH 9.0 and citrate buffer pH 6.0

    • Consider pressure cooker-based retrieval for consistent results

• Antibody concentration and incubation adjustments:

  • Extended primary antibody incubation:

    • Overnight at 4°C for IHC/IF applications

    • 48-72 hours for particularly challenging samples

  • Higher antibody concentrations:

    • For low-expression samples, use at the lower end of dilution ranges

    • For WB: 1:500 (polyclonal) or 1:5000 (monoclonal)

    • For IHC: 1:50 (polyclonal) or 1:1000 (monoclonal)

• Sample enrichment strategies:

  • Immunoprecipitation before Western blotting:

    • Use TBL1X antibodies to concentrate the protein before detection

    • Particularly useful for samples with very low expression

  • Cell sorting to isolate specific populations:

    • Enrich for cell types known to express TBL1X

    • Combine with sensitive detection methods

• Alternative detection systems:

  • Proximity ligation assay (PLA):

    • Detect TBL1X interactions with known binding partners

    • Signal amplification inherent to the technique

    • Useful when direct detection is challenging

  • Mass spectrometry-based approaches:

    • Immunoprecipitate with TBL1X antibodies

    • Analyze by mass spectrometry for increased sensitivity